We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




The Longer the Colonoscopy Takes, the Better

By HospiMedica International staff writers
Posted on 23 Jan 2014
A new study reveals that polyp and adenoma detection rates were highest when the colonoscopy withdrawal time was nine minutes long.

Researchers at the Norris Cotton Cancer Center (Lebanon, NH, USA) used data from the New Hampshire Colonoscopy Registry to examine how withdrawal time in normal colonoscopies affected adenoma and polyp detection rates. More...
A total of 7,996 colonoscopies performed in 7,972 patients, performed between 2009 and 2011 by 42 endoscopists at 14 hospitals, ambulatory surgery centers, and community practices were analyzed for associations between increased normal withdrawal time and polyp, adenoma, and clinically significant serrated polyp (CSSP) detection rates, based on median endoscopist withdrawal time.

The results showed that detection rates were highest among endoscopists with 9 minute median normal withdrawal time, and detection of CSSPs reached its highest levels at 8–9 minutes. Incident rate ratios for adenoma and CSSP detection increased with each minute of normal withdrawal time above 6 minutes, with maximum benefit at 9 minutes for adenomas and CSSPs. When modeling was used to set the minimum withdrawal time at 9 minutes, the increase in detection was most striking for the CSSPs, with nearly a 30% relative increase. The study was published early online on January 7, 2014, in the American Journal of Gastroenterology.

“Our investigation demonstrates a statistically significant correlation between longer normal withdrawal time and higher polyp detection rates, adenoma detection rates, and serrated polyp detection rates,” concluded lead author Lynn Butterly, MD, and colleagues. “It provides strong evidence to support a 9-minute median normal withdrawal time as a quality standard.”

Related Links:

Norris Cotton Cancer Center



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.